Preferred Label : Belvarafenib;
NCIt definition : An orally available inhibitor of members of the Raf family of serine/threonine protein
kinases, with potential antineoplastic activity. Upon administration, belvarafenib
binds to and inhibits the B-Raf mutant V600E and C-Raf. This inhibits B-Raf V600E-
and C-Raf-mediated signal transduction pathways, thereby inhibiting tumor cell growth
of susceptible tumor cells. In addition, belvarafenib may also inhibit mutated Ras
proteins. Raf protein kinases play a key role in the Raf/mitogen-activated protein
kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway, which
is often dysregulated in human cancers and plays a key role in tumor cell proliferation
and survival. The Raf mutation B-Raf V600E, where the valine at residue 600 is substituted
for glutamic acid, is frequently overexpressed in a variety of human tumors and results
in the constitutive activation of the Raf/MEK/ERK signaling pathway.;
UNII : 31M3WLJ3KG;
InChIKey : KVCQTKNUUQOELD-UHFFFAOYSA-N;
CAS number : 1446113-23-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1446113-23-0
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : HM95573;
Origin ID : C121646;
UMLS CUI : C5235378;
Semantic type(s)
- concept_is_in_subset
